ROR1 ADC shines at ASH Annual Meeting.

At ASH Annual Meeting, Merck announced the results of Phase II study of ROR1 ADC drug zilovertamab vedotin: in the first-line treatment of diffuse large B-cell lymphoma (DLBCL) patients, the 1.75mg/kg combination therapy dose group achieved 100% complete remission (CR). This result has triggered speculation that ROR1 ADC may reshape the treatment landscape of DLBCL.

At the same time, CStone Pharmaceuticals announced that the ROR1 ADC drug CS5001 showed positive data in advanced B-cell lymphoma that had been treated in multiple lines. The overall objective response rate (ORR) for Hodgkin lymphoma (HL) reached 60%, and all three evaluable HL patients in the 8th dose group achieved complete or partial remission. If this trend can be maintained in the future, CS5001 is expected to reshape the landscape of late-line treatment of Hodgkin lymphoma. For non-Hodgkin's lymphoma including DLBCL, the ORR was as high as 70% in the 10 evaluable patients in the 8th dose group.

Compared with zilovertamab vedotin, CS5001 has been improved in toxins and other aspects, and in the case of non-head-to-head comparison, the back-line data also showed more positive results than the former, so the market has positive expectations for the future data of CS5001.

One of the more special features of ROR1 ADC is that it spans solid tumors and hematological tumors. Studies have shown that ROR1 has a high probability of expression in a variety of solid tumors, accounting for about 50% in triple-negative breast cancer and lung adenocarcinoma.

Therefore, if the leading product performs positively, the future market potential is very worth looking forward to. For this reason, after the data of Merck and CStone Pharmaceuticals were released, the market's interest in this field began to heat up. I look forward to their better performance in the future.

https://mp.weixin.qq.com/